Travere Therapeutics (TVTX) legal chief sells 10K shares after option exercise

Rhea-AI Filing Summary

Travere Therapeutics Chief Legal Officer Elizabeth E. Reed reported an option exercise and share sale in Travere Therapeutics, Inc. common stock. On January 20, 2026, she exercised 10,000 employee stock options at an exercise price of $19.08 per share and received 10,000 shares of common stock.

That same day, she sold 10,000 shares of Travere common stock at a weighted average price of $27.3420 per share under a Rule 10b5-1(c) trading plan adopted on June 16, 2025, tied to a stock option grant from January 4, 2017 that expires on January 4, 2027. After these transactions, she directly beneficially owned 90,270 shares of common stock, which include 392 shares acquired through the 2017 Employee Stock Purchase Plan, and held 30,000 employee stock options that are fully vested and exercisable.

Insider Trade Summary

Net Seller: 10,000 shares ($273,420)

Net Sell 3 txns

Insider REED ELIZABETH E

Role Chief Legal Officer and GC

Sold 10,000 shs ($273K)

Type	Security	Shares	Price	Value
Exercise	Employee stock option (right to buy)	10,000	$0.00	--
Exercise	Common Stock	10,000	$19.08	$191K
Sale	Common Stock	10,000	$27.342	$273K

Holdings After Transaction: Employee stock option (right to buy) — 30,000 shares (Direct); Common Stock — 100,270 shares (Direct)

Footnotes (1)

1. Includes 392 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 28, 2025. This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 4, 2017 with an expiration date of January 4, 2027. The weighted average sale price for the transaction reported was $27.3420, and the range of prices were between $26.910 and $27.590. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The stock option is fully vested and exercisable.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

REED ELIZABETH E

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DR., SUITE 300

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer and GC

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		M		10,000	A	$19.08	100,270(1)	D
Common Stock	01/20/2026		S(2)		10,000	D	$27.342(3)	90,270	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$19.08	01/20/2026		M			10,000	(4)	01/04/2027	Common Stock	10,000	$0	30,000	D

Explanation of Responses:

1. Includes 392 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 28, 2025.

2. This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 4, 2017 with an expiration date of January 4, 2027.

3. The weighted average sale price for the transaction reported was $27.3420, and the range of prices were between $26.910 and $27.590. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

4. The stock option is fully vested and exercisable.

	/s/ Elizabeth E. Reed	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Travere Therapeutics (TVTX) report for Elizabeth E. Reed?

Elizabeth E. Reed, Chief Legal Officer and GC of Travere Therapeutics, Inc., reported exercising 10,000 employee stock options and selling 10,000 shares of common stock on January 20, 2026.

At what prices did Elizabeth E. Reed exercise and sell Travere Therapeutics (TVTX) shares?

She exercised options at an exercise price of $19.08 per share and sold 10,000 shares at a weighted average price of $27.3420 per share, with trade prices ranging from $26.910 to $27.590.

How many Travere Therapeutics (TVTX) shares does Elizabeth E. Reed own after the reported transactions?

Following the transactions, she directly beneficially owned 90,270 shares of Travere Therapeutics common stock, including 392 shares acquired under the 2017 Employee Stock Purchase Plan.

How many employee stock options does Elizabeth E. Reed hold in Travere Therapeutics (TVTX) after this Form 4?

After exercising 10,000 options, she held 30,000 employee stock options with an exercise price of $19.08 per share, and the filing states that the stock option is fully vested and exercisable with an expiration date of January 4, 2027.

Was the Travere Therapeutics (TVTX) insider sale by Elizabeth E. Reed under a Rule 10b5-1 trading plan?

Yes. The filing explains that the 10,000-share sale was made under a written plan adopted on June 16, 2025 that meets the requirements of Rule 10b5-1(c) under the Securities Exchange Act of 1934.

What is the origin of the Travere Therapeutics (TVTX) shares sold by Elizabeth E. Reed?

The filing states that the sale consisted of shares underlying a stock option grant awarded to her on January 4, 2017, with an expiration date of January 4, 2027.